Silicone for Implantable Medical Devices: Material Requirements, ISO 10993-6, and Long-Term Biocompatibility

Implantable medical devices represent the highest-stakes application in all of silicone manufacturing. When a silicone component is implanted in the human body — whether for days, months, or decades — every material property decision made during development becomes a patient safety commitment that cannot be recalled or revised without a surgical procedure.

The regulatory and technical requirements for implantable silicone are correspondingly more demanding than for any other medical silicone application. The biocompatibility evaluation required for a long-term implant is an order of magnitude more extensive than for a short-contact medical device. The material purity standards are stricter. The manufacturing controls are more rigorous. The documentation requirements for regulatory submission are more comprehensive. And the consequences of getting it wrong — chronic inflammation, device failure, revision surgery, patient harm — are more severe.

Yet implantable silicone is also one of the most clinically valuable materials in medicine. Silicone's unique combination of biological inertness, long-term stability in the body, mechanical flexibility, and sterilizability has made it the material of choice for pacemaker lead insulation, cochlear implant components, hydrocephalus shunts, penile implants, testicular prostheses, finger joint replacements, and hundreds of other implantable applications where no alternative material performs as well.

This guide provides the complete technical and regulatory framework for implantable silicone — covering the critical differences between medical-grade and implant-grade silicone, the full ISO 10993 biocompatibility evaluation pathway for implants, long-term stability and degradation considerations, FDA and EU MDR regulatory pathways, and the specific manufacturing requirements that distinguish implant-grade production from standard medical silicone manufacturing.

Part 1: Medical-Grade vs. Implant-Grade Silicone — A Critical Distinction

The single most important concept in implantable silicone specification is the distinction between medical-grade and implant-grade silicone. These terms are used loosely in the industry — and the confusion between them has led to serious regulatory and clinical problems.

What "Medical-Grade" Actually Means

"Medical-grade silicone" is not a legally defined term. It is a commercial designation used by silicone compound manufacturers to indicate that a compound:

• Has been manufactured under controlled conditions

• Has been tested for basic biocompatibility (typically USP Class VI and ISO 10993-5 cytotoxicity)

• Meets FDA 21 CFR 177.2600 chemical composition requirements

• Is intended for use in medical device applications

Medical-grade silicone is appropriate for non-implantable patient-contact applications — catheters, drainage tubes, respiratory circuits, IV components. It is not sufficient for implantable applications.

What "Implant-Grade" Requires

Implant-grade silicone is a higher specification that additionally requires:

The Implant-Grade Compound Suppliers

A small number of silicone compound manufacturers produce compounds specifically validated for implantable applications. The most widely used implant-grade silicone compound families include:

• Dow SILASTIC™ implant-grade compounds (e.g., SILASTIC MDX4-4210, SILASTIC Q7-4840) — the historical gold standard for implantable silicone

• Momentive (formerly GE) implant-grade compounds

• Wacker ELASTOSIL® implant-grade series

• NuSil Technology (Avantor) — specialty implant-grade compounds including fluorosilicone and high-consistency implant grades

Critical point: The implant-grade designation applies to the specific compound formulation — not to silicone in general. A device manufacturer cannot simply use any platinum-cured silicone and claim implant-grade status. The compound must be from a validated implant-grade product line with the full biocompatibility data package.

Part 2: The Full ISO 10993 Biocompatibility Evaluation for Implantable Devices

ISO 10993-1:2018 (Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process) provides the framework for biocompatibility evaluation. For long-term implantable devices, this framework requires the most extensive evaluation in the standard.

Contact Duration Classification

Most implantable silicone devices fall into the long-term (> 30 days) category — the most demanding classification.

Required ISO 10993 Endpoints for Long-Term Implantable Silicone

ISO 10993-6 — The Implantation Test

ISO 10993-6 (Tests for local effects after implantation) is the definitive test for implantable biocompatibility. It evaluates the local tissue response to a material implanted in living tissue — the most direct measure of how the body responds to the implant.

Test design:

• Test material (silicone samples) and negative control (high-density polyethylene or equivalent) are implanted subcutaneously and/or intramuscularly in rabbits or rats

• Implantation periods: 1 week, 4 weeks, 12 weeks, 26 weeks (duration depends on intended implant duration)

• At each time point, animals are sacrificed and implant sites are histologically examined

• Tissue sections are stained (H&E, Masson's trichrome) and scored for:

  • Polymorphonuclear cells (acute inflammation)

  • Lymphocytes (chronic inflammation)

  • Plasma cells

  • Macrophages

  • Giant cells (foreign body response)

  • Necrosis

  • Fibrosis (capsule thickness)

Scoring system: Each cellular response is scored 0–4 (0 = none, 4 = severe). The test material score is compared to the negative control score. The difference (reactivity score) determines the biological response classification:

What ISO 10993-6 reveals about silicone: Well-manufactured implant-grade platinum-cured silicone consistently achieves non-reactive or slightly reactive scores in ISO 10993-6 testing. The foreign body response to silicone is characterized by a thin fibrous capsule (typically 50–200μm) with minimal inflammatory infiltrate — a well-tolerated response that does not impair device function for most applications.

ISO 10993-13 — Degradation Products

ISO 10993-13 (Identification and quantification of degradation products from polymeric medical devices) requires characterization of the products that form when the implanted silicone degrades in the body over time.

Silicone degradation mechanisms in vivo:

The key finding from ISO 10993-13 for silicone: Platinum-cured silicone is among the most stable polymeric implant materials known. In vivo degradation rates are extremely low — the primary degradation products (low-MW siloxanes, silanols) are present at very low concentrations and have been extensively evaluated for toxicity. For most implantable silicone applications, the degradation risk is low and can be addressed by literature review rather than new in vivo degradation studies.

Exception — silicone gel implants: Silicone gel breast implants represent a special case where gel bleed (migration of low-MW siloxanes through the elastomer shell) has been extensively studied and regulated. The FDA requires specific gel bleed characterization for breast implants that is not required for other silicone implant types.

Part 3: Long-Term In Vivo Stability — What Happens to Silicone in the Body

Understanding the long-term behavior of silicone in the body is essential for implant design and for communicating with regulatory reviewers who will scrutinize your biocompatibility data.

The Fibrous Capsule — Normal and Abnormal Response

The body's response to any implanted foreign material is encapsulation — formation of a fibrous tissue capsule around the implant. For silicone implants:

Normal capsule formation (acceptable):

• Thin fibrous capsule: 50–300μm

• Minimal inflammatory infiltrate

• Organized collagen fibers

• No calcification

• No giant cell accumulation beyond the immediate implant surface

This is the expected response to implant-grade silicone and does not impair device function for most applications.

Capsular contracture (pathological — breast implants):

• Thick, contracted fibrous capsule: >1mm

• Significant myofibroblast infiltration

• Capsule contraction distorts implant shape and causes pain

• Baker Grade III–IV contracture requires surgical revision

• Incidence: 10–20% for smooth implants; 1–5% for textured implants over 10 years

Capsular contracture is primarily a concern for breast implants — not for most other silicone implant types. For tubular implants (shunts, leads), the capsule forms around the tube and does not cause contracture because the tube maintains its shape.

Long-Term Mechanical Stability

Silicone's mechanical properties in vivo are remarkably stable. Published data from retrieved implants (pacemaker leads, hydrocephalus shunts, penile implants) show:

Fatigue life — the critical long-term mechanical concern:For implants subject to cyclic mechanical loading — pacemaker leads (>35 million flexion cycles/year at heart rate 70 bpm), penile implants (inflation/deflation cycles), joint replacement components — fatigue failure is the primary long-term mechanical failure mode. Fatigue life must be validated by accelerated cyclic testing under worst-case loading conditions.

Calcification

Calcification (deposition of calcium phosphate minerals in or on the silicone) occurs in some long-term silicone implants, particularly:

• Silicone gel breast implants (calcification of the capsule — not the silicone itself)

• Cardiac valve leaflets (silicone-coated valves)

• Silicone hydrogel contact lenses (surface calcification)

For most solid silicone implants (shunts, leads, prostheses), calcification is not a significant clinical concern at timescales < 20 years. For applications where calcification is a concern, surface modification (plasma treatment, hydrophilic coating) can reduce calcification tendency.

Part 4: Implantable Silicone Applications — Specification by Device Type

Hydrocephalus Shunt Tubing

Hydrocephalus shunts drain excess cerebrospinal fluid (CSF) from the brain ventricles to the peritoneal cavity (VP shunt), pleural cavity (VA shunt), or right atrium (VA shunt). The silicone tubing must:

Special consideration — CSF compatibility: CSF is a low-protein, low-electrolyte fluid at body temperature. Silicone shunt tubing must not release extractables that alter CSF composition or cause meningeal irritation. The CNS is the most sensitive tissue in the body — even minor chemical irritation can cause meningitis or encephalitis. Implant-grade compound with the lowest available extractables profile is mandatory.

Cardiac Pacemaker Lead Insulation

Pacemaker leads are implanted in the heart and must function for 10–15 years (the battery life of the pacemaker generator). The silicone insulation on the lead conductor must:

The fatigue challenge: At a resting heart rate of 70 bpm, a pacemaker lead undergoes 36,792,000 flexion cycles per year. Over a 15-year device life, this is approximately 550,000,000 cycles. Fatigue life validation requires accelerated cyclic testing — typically at 3–5 Hz in a saline bath at 37°C — with electrical continuity monitoring to detect insulation failure.

Silicone vs. polyurethane for pacemaker leads: Early pacemaker leads used silicone insulation exclusively. Modern leads use either silicone, polyurethane, or co-extrusion of both. Silicone's advantages: superior long-term biostability, lower thrombogenicity, easier surgical handling. Polyurethane's advantages: thinner wall (smaller lead diameter), higher abrasion resistance. The choice depends on lead design and clinical application.

Cochlear Implant Electrode Array Carrier

The cochlear implant electrode array is inserted into the scala tympani of the cochlea — one of the most delicate surgical procedures in medicine. The silicone carrier must:

Penile and Testicular Prostheses

Silicone prostheses for erectile dysfunction and testicular replacement are among the longest-established implantable silicone applications — with clinical data spanning 40+ years.

Inflatable penile prosthesis (IPP):

• Silicone cylinders (implanted in corpora cavernosa): Shore A 25–40; implant-grade

• Silicone reservoir (implanted in prevesical space): Shore A 20–35; burst pressure ≥ 300 cmH₂O

• Silicone pump (implanted in scrotum): Shore A 30–45; 50,000+ inflation cycle fatigue life

• Full ISO 10993 long-term implant biocompatibility evaluation

Testicular prosthesis:

• Solid silicone gel or elastomer shell: Shore A 15–30 (matches natural testicular consistency)

• Implant-grade compound; ISO 10993-6 non-reactive

• Surface texture options: smooth or micro-textured

Finger Joint Replacement (Swanson Implant)

The Swanson flexible finger joint implant is a single-piece silicone hinge that replaces the metacarpophalangeal or proximal interphalangeal joint in patients with rheumatoid arthritis. It is one of the most mechanically demanding silicone implant applications:

Implant fracture — the primary failure mode: Swanson implants fracture at the hinge-stem junction under cyclic loading. Fracture rates of 20–60% have been reported at 5–10 years. Titanium grommets (sleeves placed over the stem at the hinge junction) significantly reduce fracture rates by distributing stress over a larger silicone area.

Part 5: Regulatory Pathways for Implantable Silicone Devices

United States — FDA Pathways

Class III devices (PMA — Premarket Approval):Implantable silicone devices that support or sustain human life, present a potential unreasonable risk, or are not substantially equivalent to a predicate device require PMA — the most rigorous FDA pathway.

Examples requiring PMA:

• Silicone gel breast implants

• Cochlear implants

• Inflatable penile prostheses

• Silicone-insulated cardiac leads (some)

PMA requires:

• Complete preclinical testing (full ISO 10993 long-term implant evaluation)

• Clinical trial data (IDE — Investigational Device Exemption)

• Manufacturing quality system inspection (FDA facility inspection)

• Post-approval studies (PAS) — ongoing clinical follow-up

Class II devices (510(k) — Premarket Notification):Implantable silicone devices that are substantially equivalent to a legally marketed predicate device may qualify for 510(k).

Examples eligible for 510(k):

• Hydrocephalus shunts

• Finger joint implants (Swanson-type)

• Testicular prostheses

• Silicone drainage implants (glaucoma)

510(k) for implantable devices still requires:

• Full ISO 10993 long-term biocompatibility data

• Bench testing demonstrating substantial equivalence to predicate

• Sterilization validation

• Shelf life validation

• Labeling compliance

European Union — EU MDR Pathways

Under EU MDR 2017/745, implantable devices are classified as:

Class III EU MDR requirements:

• Conformity assessment by Notified Body

• Clinical evaluation per EU MDR Article 61 — clinical data from equivalent devices or own clinical investigation

• PMCF (Post-Market Clinical Follow-up) plan

• Summary of Safety and Clinical Performance (SSCP) — publicly available

• UDI (Unique Device Identification) registration

The EU MDR clinical data requirement is the most significant change from MDD: Under the old Medical Device Directive (MDD), clinical data for implants could often be based on literature review of equivalent devices. Under EU MDR, the bar for clinical equivalence is much higher — technical, biological, and clinical equivalence must all be demonstrated. For many implantable silicone devices, this requires new clinical data collection.

Part 6: Extractables and Leachables for Implantable Silicone — The In Vivo Context

Why Implant E&L Is Different from Other Applications

For implantable devices, extractables and leachables have a fundamentally different exposure profile than for non-implantable applications:

• No dilution: Leachables from an implant are released directly into the local tissue environment — there is no dilution by blood flow or body fluids in the immediate vicinity of the implant

• Chronic exposure: The implant releases leachables continuously for the entire implant duration — years or decades

• Local concentration: Local tissue concentrations of leachables may be significantly higher than systemic concentrations

• No first-pass metabolism: Leachables absorbed from implant sites reach the systemic circulation without hepatic first-pass metabolism (unlike oral exposure)

The Implant Leachables Evaluation Framework

For implantable silicone devices, leachables evaluation follows a three-stage approach:

Stage 1: Exhaustive extraction studyExtract silicone samples under exaggerated conditions (aggressive solvents, elevated temperature, extended time) to characterize the complete extractables profile. For implant-grade silicone, key extractables of interest:

Stage 2: Toxicological Risk Assessment (TRA)For each extractable identified above the AET, conduct a TRA per ISO 10993-17. For implantable devices, the TTC is lower than for non-implantable applications — 0.15 μg/day for non-genotoxic compounds (10× lower than the 1.5 μg/day TTC for non-implantable devices) due to the chronic local exposure.

AETimplant=0.15 μg/dayDaily Release Rate (mg/day)×Safety FactorAETimplant=Daily Release Rate (mg/day)×Safety Factor0.15μg/day

Stage 3: In vivo confirmationISO 10993-6 implantation testing provides in vivo confirmation that the extractables profile does not cause unacceptable local tissue response. The histological scoring at 26 weeks reflects the cumulative effect of all leachables released during the implantation period.

Part 7: Manufacturing Requirements for Implant-Grade Silicone Components

Implant-grade silicone manufacturing requires controls that go beyond standard medical device manufacturing. The following requirements are specific to implantable applications.

Cleanroom Requirements

Surface Quality Requirements

Implant surfaces must meet stringent cleanliness and finish requirements:

Particulate cleanliness: Implant surfaces must be free of particulates that could cause foreign body reactions. Particulate limits for implantable devices are significantly stricter than for non-implantable devices — typically ≤ 1 particle > 25μm per device for Class III implants.

Surface roughness: Smooth implant surfaces (Ra ≤ 0.8μm for most applications) minimize tissue trauma during implantation and reduce fibrous capsule formation. For cochlear implant carriers, Ra ≤ 0.2μm is required.

Visual inspection: 100% visual inspection under magnification (typically 10× loupe) for surface defects — inclusions, voids, surface cracks, flash, or contamination. Automated vision systems are used for high-volume implant components.

Lot Traceability and Change Control

For implantable devices, lot traceability and change control requirements are the most stringent in medical device manufacturing:

Lot traceability: Complete traceability from finished implant to raw material lot — including silicone compound lot, platinum catalyst lot, filler lot, and any colorant or additive lots. This traceability must be maintained for the lifetime of the implant (potentially 20+ years) plus the required post-market surveillance period.

Change control: Any change to the silicone compound formulation, raw material supplier, manufacturing process, or sterilization method requires:

• Formal change control documentation

• Risk assessment of the change's impact on biocompatibility, performance, and safety

• Re-testing as required by the risk assessment (potentially including new ISO 10993-6 implantation studies)

• Regulatory notification or submission (PMA supplement for Class III devices; 510(k) for significant changes to Class II devices)

For a complete guide to supplier qualification and change control requirements for medical silicone manufacturers, see: How to Choose a Reliable Medical Silicone Manufacturer in China

Sterilization Validation for Implantable Devices

Implantable devices must be supplied sterile with SAL 10−610−6. Sterilization method selection and validation requirements:

EtO residuals for implants: The EtO residual limit for implantable devices is 0.1 mg/device — the same as the inhalation limit and 20× stricter than the limit for non-implantable, non-inhalation devices. Extended aeration (typically 14–30 days at room temperature) is required.

For a complete guide to sterilization method selection and validation, see: Sterilization Methods for Medical Silicone Products: Autoclave, EtO, Gamma, and E-Beam Compared

Part 8: Supplier Qualification for Implant-Grade Silicone

Qualifying a silicone supplier for implantable device manufacturing is the most rigorous supplier qualification process in medical device procurement. The following framework covers the key elements beyond standard medical device supplier qualification.

Documentation Requirements Specific to Implant-Grade

• Implant-grade compound designation — written confirmation from compound manufacturer that the specific compound is designated for implantable use

• Compound manufacturer's biocompatibility data package — full ISO 10993 data for the compound (not just USP Class VI)

• ISO 10993-6 implantation test report — for the specific compound, at 26-week time point

• ISO 10993-13 degradation study — characterization of in vitro and in vivo degradation products

• ISO 10993-17 toxicological risk assessment — TRA for all identified extractables above implant AET

• Compound change notification history — any changes to the compound formulation in the past 10 years

• Lot-to-lot consistency data — extractables data from minimum 5 consecutive production lots

• Long-term stability data — accelerated aging or real-time aging data for the compound

Audit Focus Areas for Implant-Grade Suppliers

In addition to standard medical device audit elements, implant-grade supplier audits must specifically address:

Compound segregation: Implant-grade compound must be physically segregated from non-implant-grade compound — separate storage, separate handling equipment, separate production lines or validated changeover procedures. Cross-contamination of implant-grade compound with non-implant-grade material is a critical quality failure.

Cleanroom qualification: Verify ISO Class 7 cleanroom certification with continuous particle monitoring. For implant-grade production, request particle count data from the past 12 months — not just the most recent report.

Personnel qualification: Implant-grade production personnel must have documented training specific to implant-grade requirements — not just general medical device manufacturing training.

Change control records: Request the change control log for the past 5 years. Any undisclosed changes to compound, process, or supplier are a major audit finding for implant-grade qualification.

For a complete remote audit protocol including implant-specific verification steps, see: How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer

Chensheng Medical Implant-Grade Silicone Capabilities

Jinan Chensheng Medical Technology Co., Ltd. manufactures implant-grade silicone components for global medical device companies developing implantable devices. Our implant-grade manufacturing capability operates under the highest quality standards in our facility.

Implant-grade product range:

Our implant-grade manufacturing standard:

• Implant-grade platinum-cured silicone compound (Dow SILASTIC or equivalent validated implant-grade)

• ISO Class 7 cleanroom — dedicated implant-grade production areas

• ISO 13485 quality management system with implant-specific procedures

• Full ISO 10993 biocompatibility documentation package

• Complete lot traceability to raw material

• EtO and gamma sterilization available via qualified contract sterilizers

→ Discuss Your Implantable Device Silicone Requirements→ Request Our Implant-Grade Biocompatibility Documentation→ Submit Your Implant Component Drawing for DFM Review

Frequently Asked Questions (FAQ)

Q1: What is the difference between medical-grade and implant-grade silicone, and can I use medical-grade silicone for a short-term implant?

A: Medical-grade silicone meets basic biocompatibility requirements (USP Class VI, ISO 10993-5 cytotoxicity, FDA 21 CFR 177.2600) suitable for non-implantable patient-contact applications. Implant-grade silicone additionally requires ISO 10993-6 implantation testing, long-term systemic toxicity evaluation (ISO 10993-11 chronic), genotoxicity and carcinogenicity assessment (ISO 10993-3), degradation product characterization (ISO 10993-13), and a full toxicological risk assessment (ISO 10993-17). For any implantable application — even short-term implants (< 30 days) — implant-grade compound and the corresponding biocompatibility data are required. Using medical-grade silicone for an implantable application without the full ISO 10993 implant evaluation is a regulatory non-compliance that will be identified in FDA or Notified Body review.

Q2: How long does a full ISO 10993 biocompatibility evaluation for a long-term implant take?

A: A complete ISO 10993 biocompatibility evaluation for a long-term implantable silicone device typically takes 12–24 months from study initiation to final report. The longest individual study is the chronic systemic toxicity study (ISO 10993-11) — typically a 12-month repeat-dose study in rodents. The ISO 10993-6 implantation study at 26 weeks adds 6 months. Genotoxicity studies (Ames test, mouse lymphoma, chromosome aberration) take 3–4 months. Carcinogenicity assessment can often be addressed by literature review rather than a new 2-year bioassay, which would otherwise add 2+ years. For device developers, the biocompatibility timeline is often the critical path in implant development — it should be initiated as early as possible, ideally using the final compound and manufacturing process to avoid re-testing.

Q3: Can I use existing published biocompatibility data for implant-grade silicone compounds rather than conducting new studies?

A: Yes — for well-characterized implant-grade compounds (Dow SILASTIC, NuSil implant-grade series), extensive published and proprietary biocompatibility data exists. FDA and EU MDR both allow the use of existing data through a formal biocompatibility evaluation that assesses whether the existing data is applicable to your specific device. The key requirements for using existing data: (1) the data must be for the same compound formulation — not a similar compound; (2) the manufacturing process must be the same or demonstrably equivalent; (3) the sterilization method must be the same; (4) the contact duration and tissue type must be the same or more demanding than your application. In practice, most implant-grade silicone biocompatibility evaluations combine existing compound-level data with device-specific testing (particularly ISO 10993-6 implantation on the finished, sterilized device).

Q4: What is the FDA's current position on silicone gel breast implants, and does it affect other silicone implant approvals?

A: FDA's current position on silicone gel breast implants (updated 2021 guidance) requires: black box warning about risks including BIA-ALCL (breast implant-associated anaplastic large cell lymphoma) and breast implant illness; patient decision checklist; MRI screening recommendations; and post-approval studies. These requirements are specific to breast implants and do not directly affect FDA's evaluation of other silicone implant types. However, the breast implant controversy has increased FDA's scrutiny of all silicone implant submissions — reviewers are more likely to request additional long-term safety data, post-market surveillance commitments, and patient labeling for any silicone implant submission. Device developers should anticipate more rigorous FDA review and plan their clinical and preclinical data packages accordingly.

Q5: What are the EU MDR requirements for clinical data for a new silicone implant?

A: Under EU MDR Article 61, Class III implantable devices require clinical data from: (1) clinical investigation of the device itself; or (2) clinical data from an equivalent device, where equivalence is demonstrated on technical, biological, and clinical grounds with sufficient detail to justify the equivalence claim. The EU MDR equivalence standard is significantly stricter than the previous MDD standard — "equivalent" now requires the same intended purpose, same design principles, same materials in contact with the same tissues, and similar clinical performance. For most new silicone implant designs, demonstrating equivalence to an existing device is difficult, making a new clinical investigation the practical path. The SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks) opinion on silicone safety provides the scientific basis for the biological equivalence argument for silicone implants using established implant-grade compounds.

Q6: How do I specify the correct Shore A hardness for an implantable silicone component?

A: Shore A selection for implantable silicone follows the same principles as for non-implantable applications — balance of flexibility, mechanical integrity, and functional requirements — but with additional constraints: (1) the compound must be available in implant-grade designation at the target hardness; (2) the biocompatibility data must cover the specific hardness (different hardness grades of the same compound family may have different filler levels and therefore different extractables profiles); (3) for applications with cyclic mechanical loading, the hardness must be validated for fatigue life at the target hardness. For most soft tissue implants (prostheses, shunts), Shore A 25–55 is the practical range. For mechanically loaded implants (joint replacements, pacemaker leads), Shore A 55–70 is typical. For ultra-soft applications (testicular prostheses, cochlear implant carriers), Shore A 5–30 is used. See our complete Shore A selection guide: Silicone Shore A Hardness Explained: How to Select the Right Durometer for Your Medical Application

Q7: What post-market surveillance is required for implantable silicone devices?

A: Post-market surveillance (PMS) requirements for implantable silicone devices are the most extensive in medical device regulation. Under FDA PMA, post-approval studies (PAS) are typically required — ongoing clinical follow-up of implanted patients at defined intervals (1 year, 3 years, 5 years, 10 years) to monitor long-term safety and performance. Under EU MDR, a Post-Market Clinical Follow-up (PMCF) plan is mandatory for all Class III implants, with annual PMCF reports submitted to the Notified Body. For silicone implants specifically, PMS should monitor: revision/explantation rates and reasons; adverse events (capsular contracture, implant fracture, migration, infection); long-term biocompatibility signals (unexpected tissue reactions, systemic effects); and device performance over time. PMS data feeds back into the clinical evaluation and risk management file, which must be updated at least annually for Class III devices.

Related Articles:

• Platinum-Cured vs. Peroxide-Cured Silicone: Which Is Better for Your Application?

• USP Class VI, ISO 10993, and FDA 21 CFR 177.2600: Which Certification Do You Actually Need?

• Sterilization Methods for Medical Silicone Products: Autoclave, EtO, Gamma, and E-Beam Compared

• Silicone Shore A Hardness Explained: How to Select the Right Durometer for Your Medical Application

• Medical Silicone Extrusion vs. Injection Molding vs. Compression Molding: Which Process Is Right for Your Component?

• Silicone Tubing for Pharmaceutical Manufacturing: Extractables, Leachables, and Regulatory Compliance

• How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer

• How to Choose a Reliable Medical Silicone Manufacturer in China